Fecal transplant plus fiber to treat graft-versus-host disease after blood stem cell transplant
Official title: Fecal Microbiota Transplantation and Fiber for the Treatment of Graft-versus-host Disease After Hematopoietic Cell Transplantation
Funded at Fred Hutchinson Cancer Center · NIH-11377663 · Data updated 2026-11-12
A study to see if giving fecal transplant along with dietary fiber helps gut health and reduces complications in patients who have received a stem cell transplant and developed graft-versus-host disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $627,095 |
| NIH project number | 5R01HL166107-04 |
| Project ID | NIH-11377663 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults who have undergone allogeneic hematopoietic cell transplantation and have or are at risk for GvHD.
✕Less likely to help
Patients without GvHD or those who cannot tolerate gut-directed therapies may derive little or no direct benefit.
What this research studies
This project focuses on people who have undergone allogeneic hematopoietic cell transplantation and develop GvHD, a serious complication. It aims to test how delivering FMT (fecal microbiota transplant) and fiber affects gut bacteria, inflammation, and clinical outcomes. Researchers will compare different delivery methods, monitor safety, and examine how the gut microbiome changes relate to recovery. The study uses controlled approaches to understand whether gut bacteria can influence GvHD progression and patient well-being.
Why it matters
Potential benefit: If successful, patients with GvHD after transplant could experience better gut health, fewer complications, and improved quality of life.
How similar studies have gone: Prior observational data and animal studies suggest gut microbiota manipulation may affect GvHD outcomes, but controlled evidence is limited and this trial seeks to provide more definitive data.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Fredricks, David Neal — Fred Hutchinson Cancer Center
- Study coordinator: Fredricks, David Neal
Related research
Other NIH-funded projects on the same topics.
-
Using Fecal Microbiota Transplantation and Fiber to Treat Graft-versus-host Disease After Stem Cell Transplants
This work explores how giving patients healthy gut bacteria and fiber might help manage graft-versus-host disease, a common issue after stem cell transplants.
-
Using fecal microbiota transplantation and fiber to treat graft-versus-host disease after blood cell transplants
This study is looking at how using a special treatment called fecal microbiota transplantation, along with dietary fiber, can help improve gut health and recovery for patients dealing with graft-versus-host disease after a stem cell transplant.
-
Proteolytic Activity-Guided Fecal Microbiota Transplant for PI-IBS
A pilot study will test a targeted fecal microbiota transplant to help adults with post-infection irritable bowel syndrome feel better and have fewer GI symptoms.
-
Fecal microbiota transplantation plus immune checkpoint blockers for solid tumors
This project looks at whether changing gut bacteria with fecal transplants can boost how well cancer treatments called immune checkpoint blockers work in people with solid tumors.
-
Fecal transplant treatment for auto-brewery (gut fermentation) syndrome
This project gives capsule fecal microbiota transplants to adults with auto-brewery syndrome to try to stop their gut from producing alcohol and causing unexplained intoxication.
-
A new way to use gut bacteria transplants for Irritable Bowel Syndrome
This research explores if a special type of fecal microbiota transplant, guided by specific gut enzyme activity, can safely and effectively improve symptoms for adults with Irritable Bowel Syndrome that developed after an infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.